PDE4D, phosphodiesterase 4D, 5144

N. diseases: 210; N. variants: 68
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.320 Biomarker disease CTD_human Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. 29662167 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.320 Biomarker disease BEFREE Overall, our findings highlight the relevance of PDE4D as prostate cancer biomarker and potential drug target. 27683107 2016
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.320 Biomarker disease BEFREE The effects of PDE4D inhibitors on pathways that are critical in prostate cancer and/or downstream of cyclic AMP (cAMP) were examined. 25149359 2015
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.320 Biomarker disease CTD_human Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. 16740699 2006